Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Akorn, GeneraMedix Sign Manufacturing Pact | Contract Pharma
Breaking News

Akorn, GeneraMedix Sign Manufacturing Pact

Akorn, Inc. has signed a commercial manufacturing supply agreement with GeneraMedix, Inc. to manufacture injectable products in finished dosage form for GeneraMedix. Under the agreement, GeneraMedix will market these products in the GeneraMedix label. The agreement includes products currently available from Akorn, as well as select injectable products from the Akorn internal product development pipeline.

Arthur S. Przybyl, president and chief executive officer of Akorn stated, “We are excited to enter into this strategic product supply partnership with GeneraMedix. This partnership will allow us to expand our existing market share and increase our contract sales revenues. We believe that GeneraMedix and their executive management team have the experience and infrastructure to successfully market these generic products to the hospital and specialty pharmaceutical markets. We look forward to a long-standing and successful relationship.”

Ronald F. Quadrel, president and chief executive officer of GeneraMedix stated, “We are very pleased to enter into this strategic relationship with Akorn as we continue to build our injectable product portfolio. The addition of these products reinforces our long term commitment to provide a broad range of generic injectable products to hospitals, surgery centers and clinics.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters